Table 2.

Tumor response: all patients, GBM patients, and AA patients (primary efficacy population)

Tumor response	Number of patients (%)
	10 µM trabedersen	80 µM trabedersen	Standard chemotherapy (TMZ/PCV)
All patients	n = 40	n = 49	n = 45
6 months
Tumor control rate (CR + PR + SD)	13 (33%)	10 (20%)	12 (27%)
Overall response rate (CR + PR)	2 (5%)	3 (6%)	3 (7%)
Progressive disease	19 (48%)	34 (69%)	23 (51%)
Missing MRI data	8 (20%)	5 (10%)	9 (20%)
14 months
Tumor control rate (CR + PR + SD)	9 (23%)	4 (8%)	3 (7%)
Overall response rate (CR + PR)	6 (15%)	3 (6%)	2 (4%)
Progressive disease	22 (55%)	31 (63%)	32 (71%)
Missing MRI data	9 (23%)	14 (29%)	10 (22%)
GBM patients	n = 28	n = 34	n = 33
6 months
Tumor control rate (CR + PR + SD)	4 (14%)	4 (12%)	5 (15%)
Overall response rate (CR + PR)	0	1 (3%)	0
Progressive disease	16 (57%)	26 (77%)	19 (58%)
Missing MRI data	8 (29%)	4 (12%)	8 (24%)
14 months
Tumor control rate (CR + PR + SD)	2 (7%)	1 (3%)	3 (9%)
Overall response rate (CR + PR)	1 (4%)	0	2 (6%)
Progressive disease	20 (71%)	25 (74%)	25 (76%)
Missing MRI data	6 (21%)	8 (24%)	5 (15%)
AA patients	n = 12	n = 15	n = 12
6 months
Tumor control rate (CR + PR + SD)	9 (75%)	6 (40%)	7 (58%)
Overall response rate (CR + PR)	2 (17%)	2 (13%)	3 (25%)
Progressive disease	3 (25%)	8 (53%)	4 (33%)
Missing MRI data	0	1 (7%)	1 (8%)
14 months
Tumor control rate (CR + PR + SD)	7 (58%)	3 (20%)	0
Overall response rate (CR + PR)	5 (42%)	3 (20%)	0
Progressive disease	2 (17%)	6 (40%)	7 (58%)
Missing MRI data	3 (25%)	6 (40%)	5 (42%)

AA, anaplastic astrocytoma; GBM, glioblastoma; PCV, procarbazine/CCNU (lomustine)/vincristine; TMZ, temozolomide; CR, complete response; PR, partial response; SD, stable disease.